Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase NA 1Phase 1/2 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1CNS 1

Conditions

Brain Neoplasms 3Neoplasms 2Central Nervous System Neoplasms 2Carcinoma, Renal Cell 2Breast Neoplasms 2Unspecified Adult Solid Tumor, Protocol Specific 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1Oligodendroglioma 1Melanoma 1Lung Neoplasms 1Hematologic Neoplasms 1Glioma 1Glioblastoma 1Ependymoma 1Disease 1Carcinoma, Non-Small-Cell Lung 1Astrocytoma 1

Interventions

pembrolizumab 82Paclitaxel 71Gemcitabine 66Carboplatin 61Cisplatin 46Docetaxel 44Bevacizumab 41Nivolumab 33Irinotecan 31Fluorouracil 29Pemetrexed 28Cyclophosphamide 26Cetuximab 26Capecitabine 26Erlotinib Hydrochloride 22venetoclax 21trametinib 21Leucovorin 20Sorafenib 17Albumin-Bound Paclitaxel 17Afatinib 17130-nm albumin-bound paclitaxel 17Topotecan 16Radiotherapy 16Oxaliplatin 16fludarabine 15regorafenib 14budigalimab 14atezolizumab 14Ipilimumab 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Neoplasms × alovudine × Clear all
NCT00880074 2023-06-26

FLT-PET in Predicting Response to Chemotherapy in Patients With Advanced Malignancies

M.D. Anderson Cancer Center

Phase 1 Completed
10 enrolled
Tumor-Agnostic

Neoplasms

NCT00813566 2022-04-27

Multi-Tracer PET Assessment of Primary Brain Tumors

University of Utah

Phase 1 Completed
11 enrolled
CNS

Brain Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡